Professor Keith Martin

Mirugen Secures A$4.5m to Pioneer Cell (Re)programming, and Welcomes Charlotte Casebourne Stock as Executive Chair

Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.

Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au

Investment update: Cerulea

Breakthrough Victoria marks the opening of an eye research facility it backed with $10 million; the CERA-affiliated centre expects to treat thousands of patients and create dozens of jobs.